ANI Operating Income vs Cost of Revenue Analysis
ANIP Stock | USD 64.58 0.90 1.37% |
ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Operating Income and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
Operating Income vs Cost Of Revenue
Operating Income vs Cost of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Operating Income account and Cost of Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between ANI Pharmaceuticals' Operating Income and Cost of Revenue is 0.46. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Cost of Revenue in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Operating Income and Cost of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of ANI Pharmaceuticals are associated (or correlated) with its Cost of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost of Revenue has no effect on the direction of Operating Income i.e., ANI Pharmaceuticals' Operating Income and Cost of Revenue go up and down completely randomly.
Correlation Coefficient | 0.46 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Operating Income
Operating Income is the amount of profit realized from ANI Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ANI Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Cost Of Revenue
Cost of Revenue is found on ANI Pharmaceuticals income statement and represents the costs associated with goods and services ANI Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.As of 04/19/2024, Selling General Administrative is likely to grow to about 157.9 M, while Discontinued Operations is likely to drop slightly above 156 K.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 115.5M | 177.6M | 245.5M | 257.8M | Total Revenue | 216.1M | 316.4M | 486.8M | 511.2M |
ANI Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
ANI Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ANI Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Liab | 36.7M | 54.0M | 63.6M | 69.3M | 99.8M | 104.8M | |
Total Current Liabilities | 61.7M | 78.6M | 87.5M | 99.4M | 145.5M | 152.8M | |
Total Stockholder Equity | 212.8M | 195.7M | 358.7M | 338.5M | 432.7M | 454.4M | |
Property Plant And Equipment Net | 40.6M | 41.3M | 52.7M | 43.2M | 44.6M | 46.8M | |
Net Debt | 123.4M | 177.8M | 187.1M | 238.3M | 94.2M | 98.9M | |
Retained Earnings | 17.6M | (5.0M) | (47.8M) | (97.3M) | (80.1M) | (84.1M) | |
Accounts Payable | 14.6M | 11.3M | 23.0M | 29.3M | 36.7M | 38.5M | |
Cash | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Non Current Assets Total | 269.1M | 290.9M | 449.8M | 415.8M | 384.8M | 404.0M | |
Cash And Short Term Investments | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Common Stock Shares Outstanding | 12.0M | 12.0M | 12.6M | 16.3M | 18.2M | 19.1M | |
Liabilities And Stockholders Equity | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Assets | 5.1M | 5.9M | 11.3M | 8.4M | 25.2M | 26.5M | |
Total Liab | 244.0M | 265.5M | 412.9M | 421.5M | 471.7M | 495.3M | |
Property Plant And Equipment Gross | 40.6M | 41.3M | 75.6M | 76.0M | 77.5M | 81.4M | |
Total Current Assets | 187.7M | 170.3M | 321.8M | 344.3M | 519.6M | 545.6M | |
Other Stockholder Equity | 200.1M | 212.1M | 384.7M | 398.8M | 479.2M | 503.1M | |
Accumulated Other Comprehensive Income | (4.9M) | (11.4M) | (3.1M) | 12.2M | 8.9M | 9.3M | |
Short Long Term Debt Total | 185.7M | 185.7M | 287.4M | 286.5M | 315.3M | 331.1M | |
Short Term Debt | 115.7M | 9.9M | 13.2M | 850K | 977.5K | 928.6K | |
Current Deferred Revenue | 451K | 80K | 87K | 8.2M | 9.4M | 9.9M | |
Non Currrent Assets Other | 1.2M | 802K | 2.2M | 2.6M | 12.3M | 12.9M | |
Non Current Liabilities Total | 182.3M | 186.9M | 325.3M | 322.1M | 326.2M | 342.5M | |
Net Receivables | 72.1M | 95.8M | 128.5M | 165.4M | 162.1M | 170.2M | |
Net Tangible Assets | 28.8M | 3.6M | 36.7M | 58.7M | 52.8M | 55.5M | |
Other Assets | 44.6M | 57.5M | 75.1M | 92.7M | 106.6M | 112.0M | |
Long Term Debt | 175.8M | 172.4M | 286.5M | 285.7M | 284.8M | 149.2M | |
Retained Earnings Total Equity | 17.6M | (5.0M) | (47.8M) | (97.3M) | (111.9M) | (117.5M) | |
Inventory | 48.2M | 60.8M | 81.7M | 105.4M | 111.2M | 116.8M | |
Deferred Long Term Liab | 1.5M | 800K | 500K | 600K | 690K | 458.1K | |
Intangible Assets | 180.4M | 188.5M | 294.1M | 251.6M | 209.0M | 156.5M | |
Property Plant Equipment | 40.6M | 41.3M | 52.7M | 43.2M | 49.7M | 52.2M | |
Capital Surpluse | 200.8M | 214.4M | 387.8M | 403.9M | 464.5M | 237.5M | |
Other Liab | 7K | 201K | 31.0M | 35.1M | 40.3M | 42.3M |
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ANI Stock
0.9 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
0.74 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
0.71 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
Moving against ANI Stock
0.96 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
0.88 | ME | 23Andme Holding | PairCorr |
0.88 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
0.88 | DRUG | Bright Minds Biosciences | PairCorr |
0.85 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share 0.85 | Revenue Per Share 27.044 | Quarterly Revenue Growth 0.397 | Return On Assets 0.0372 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.